2017 Buyer’s Guide

This buyer’s guide offers a searchable, comprehensive listing of the FDA-approved interventional devices available in the United States.

Teleflex's Spectre Guidewire Cleared by FDA

 

March 15, 2017—Teleflex Incorporated announced US Food and Drug Administration 510(k) clearance and the United States commercial launch of the Spectre guidewire. The Spectre guidewire is intended for use in percutaneous procedures to introduce and position catheters and other interventional devices within the coronary and/or peripheral vasculature.

According to Teleflex, the 0.014-inch Spectre guidewire is available in 190- and 300-cm lengths. The device has a distal hydrophilic coating and a proximal polytetrafluoroethylene coating. The guidewire's smooth stainless steel–to-nitinol dual-core transition balances strength and agility. The Spectre was designed to be a workhorse guidewire, applicable to the majority of percutaneous coronary interventions.

The device's proximal stainless steel core combines pushability with support for optimal delivery. Additionally, the distal nitinol core is flexible and kink resistant for increased durability. The combination provides trackability and torque control, stated the company.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.